Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers of chronic lymphocytic leukemia and use thereof

a technology biomarkers, which is applied in the field of chronic lymphocytic leukemia biomarkers, can solve the problems of the likelihood of significant deterioration of the disease in cll-diagnosed patients, and achieve the effects of reducing the expression or activity of adh5, reducing the expression or activity of bri3b, and reducing the expression or activity of idh3a

Active Publication Date: 2020-08-27
THE NAT INST FOR BIOTECH IN THE NEGEV LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a combination of proteins that can be used as a diagnostic tool for chronic lymphocytic leukemia (CLL). The proteins DDX46, AK3, AP3B1, ADH5, BRI3B, IDH3A, SNX18, RPE, and PPWD1 were found to be increased, while the level of LTBP1 was decreased in patients with CLL. The expression level of other proteins, such as SNX18, DHRS4, TBL2, and RPE, were found to be associated with a likelihood of significant deterioration of the disease. The combination of proteins described in the patent can provide a precise and adequate diagnosis for CLL. Additionally, the patent provides a method of treating CLL by reducing the expression or activity of PPWD1.

Problems solved by technology

In addition, an increase in the expression of SNX18, DHRS4, TBL2, and RPE proteins and decrease in the expression of ENPP4 were found to be associated with a likelihood of significant deterioration of the disease in CLL-diagnosed patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers of chronic lymphocytic leukemia and use thereof
  • Biomarkers of chronic lymphocytic leukemia and use thereof
  • Biomarkers of chronic lymphocytic leukemia and use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

rofiling in PBMCs from CLL Patients and Healthy Donors

[0197]PBMCs isolated from healthy donors and CLL patients receiving no disease treatment were analyzed using LC-HR-MS / MS and immunoblotting to explore possible CLL biomarkers and disease progression predication. PBMC samples were collected from six healthy individuals and nineteen CLL patients. Hierarchical clustering based on the protein expression pattern clearly allowed for distinction between the healthy donors and the CLL patients, with the expression level of 1,360 proteins being changed (fold change (FC)≥121 and p-value<0.01, of which 118 with a FC≥100).

[0198]Next, functional analysis of proteins differentially expressed between healthy donors and CLL patients was performed using the DAVID tool based on the KEGG databases (Kanehisa M et al., Nucleic Acids Res. 2000; 28(1):27-30; Kanehisa M et al., Nucleic Acids Res. 2014, 42:D199-205; Ashburner M et al., Nature genetics. 2000; 25:25-9; Consortium TGO. Nucleic Acids Res. 20...

example 2

ation of Novel Bio-Markers for CLL

[0199]To further select proteins for continued focus, the LC-HR-MS / MS analysis was repeated using 14 samples (from five age-correlated healthy donors and nine CLL patients) that included new as well as previously analyzed samples. This narrowed the focus to 59 proteins that presented a clear common expression pattern in both LC-HR-MS / MS analyses. These proteins include several proteins that have previously been identified as being mutated in CLL or proposed as CLL diagnosis and prognosis markers (Table 1). A protein that induces tumorigenesis through p53 stabilization but was not previously found to correlated with CLL is a putative peptidylprolyl isomerase (PPlase, PPWD1) that accelerates the folding of proteins and may be involved in pre-mRNA splicing. FIG. 1 demonstrates that PPWD1 protein expression is highly elevated in CLL patients.

[0200]Several proteins whose expression levels were significantly different between healthy and CLL patients were...

example 3

s Analysis Allows Distinction Between Patients in a Stable Disease State and Those Transferred to Anti-Cancer Treatment or Who Died

[0203]Of the PBMCs derived from 19 CLL patients subjected to LC-HR-MS / MS analysis, 10 patients were in a stable disease state and needed no treatment 2-3 years after blood samples were obtained. Nine patients were subjected to treatment or died 0.5 to 36 months after collection of blood samples. Thus, to further identify proteins that allow to distinguish between patients in a stable disease state (group A) from those transferred to anti-cancer treatment or who died (group B), the protein expression profile of these two groups was analyzed. Hierarchical clustering of all 19 CLL samples could not properly separate between groups A and B. Yet, a volcano chart derived from a t-test with equal variances analysis revealed 50 proteins whose expression levels were significantly different between the two groups (FC≥|2|, p-value<0.01) (FIG. 5). Nineteen of the 50...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention provides novel biomarkers of chronic lymphocytic leukemia (CLL). Specifically, the present invention provides methods and kits for diagnosing, assessing the level of severity, and treating of CLL.

Description

FIELD OF THE INVENTION[0001]The present invention relates to biomarkers of chronic lymphocytic leukemia. In particular, the present invention relates to means and methods for diagnosing, assessing the level of severity and treating of chronic lymphocytic leukemia.BACKGROUND OF THE INVENTION[0002]Chronic lymphocytic leukemia (CLL), a B cell non-Hodgkin's lymphoma with a leukemic appearance, is the most common leukemia of adults in Western countries, with median age at diagnosis ranging between 67 and 72 years. Recent data indicate that approximately 6% of the normal elderly population develops a monoclonal B-cell lymphocytosis (MBL), which can transform into CLL in 1%-2% of cases. The clinical course is highly variable, ranging from very indolent cases to patients with aggressive and rapidly progressing disease. This heterogeneity has important consequences which impacts clinical approaches, treatment strategies, and survival time from diagnosis.[0003]CLL patients are currently categ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/49
CPCA61K45/06G01N2800/56G01N33/49G01N2800/52C12Q1/6886C12Q2600/158C12Q2600/112C12N15/113G01N33/57426C12N2310/14G01N2800/50A61P35/00C12N15/1135A61K48/00C07K16/00
Inventor SHOSHAN-BARMATZ, VARDA
Owner THE NAT INST FOR BIOTECH IN THE NEGEV LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com